title: The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development.
authors.affiliation: U.S. Food and Drug Administration, Silver Spring, Maryland. Electronic address: Norman.stockbridge@fda.hhs.gov.
authors.forename: Norman
authors.initials: N
authors.lastname: Stockbridge
authors.affiliation: U.S. Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Kristen
authors.initials: K
authors.lastname: Miller
authors.affiliation: U.S. Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Shashi
authors.initials: S
authors.lastname: Amur
authors.affiliation: U.S. Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Matthew
authors.initials: M
authors.lastname: Hillebrenner
authors.affiliation: U.S. Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Bram
authors.initials: B
authors.lastname: Zuckerman
authors.affiliation: U.S. Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Mona
authors.initials: M
authors.lastname: Fiuzat
authors.affiliation: U.S. Food and Drug Administration, Silver Spring, Maryland.
authors.forename: Robert M
authors.initials: RM
authors.lastname: Califf
mesh_terms: D002317:Cardiovascular Agents / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D011786:Quality Control; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D002317:Cardiovascular Agents
keywords: FDA; drug evaluation; stroke